Journal for ImmunoTherapy of Cancer

Title Publication Date Language Citations
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment2014/01/01English409
Myeloid derived suppressor cells – a new therapeutic target in the treatment of cancer2013/01/01English213
The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma2014/01/01English118
Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells2014/01/01English99
Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy2014/01/01English86
Opportunistic infections in patients treated with immunotherapy for cancer2014/01/01English83
Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer2014/01/01English80
Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts2013/01/01English71
Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program2014/01/01English69
Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy2013/01/01English51
Combination therapy targeting toll like receptors 7, 8 and 9 eliminates large established tumors2014/01/01English48
Immune monitoring using the predictive power of immune profiles2013/01/01English41
The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cells2014/01/01English38
Immunoglobulin-like transcript 2 (ILT2) is a biomarker of therapeutic response to oncolytic immunotherapy with vaccinia viruses2014/01/01English28
Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma2013/01/01English27
A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma2013/01/01English27
Cytokine responsiveness of CD8+ T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients2014/01/01English26
Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb2013/01/01English26
Turning T cells on: epigenetically enhanced expression of effector T-cell costimulatory molecules on irradiated human tumor cells2013/01/01English22
A melanoma helper peptide vaccine increases Th1 cytokine production by leukocytes in peripheral blood and immunized lymph nodes2014/01/01English19
Oncogene withdrawal engages the immune system to induce sustained cancer regression2014/01/01English16
Regulation of immunotherapeutic products for cancer and FDA’s role in product development and clinical evaluation2013/01/01English15
PET imaging to non-invasively study immune activation leading to antitumor responses with a 4-1BB agonistic antibody2013/01/01English12
Strategies for improving the reporting of human immunophenotypes by flow cytometry2014/01/01English11
Cellular immunity induced by a recombinant adenovirus- human dendritic cell vaccine for melanoma2013/01/01English4
Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H32015/01/01English2
Focus on the target: the tumor microenvironment, Society for Immunotherapy of Cancer Annual Meeting Workshop, October 24th-25th 20122013/01/01English2
Imprime PGG, a yeast β-glucan immunomodulator, has the potential to repolarize human monocyte-derived M2 macrophages to M1 phenotype2014/01/01English1
FAK/PYK2 inhibitors defactinib and VS-4718 enhance immune checkpoint inhibitor efficacy2015/01/01English1
Reovirus activated NK cells show enhanced cetuximab mediated antibody-dependent cellular cytotoxicity against colorectal cancer cells2015/01/01English1